Moanaro Biswas

Moanaro Biswas

Auto-generated profile, based on publicly available information

Moanaro Biswas

Herman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
SKSandeep Rp Kumar
Sandeep Rp Kumar
DMDavid M Markusic
David M Markusic
MBMoanaro Biswas
Moanaro Biswas
KHKatherine A High
Katherine A High
RHRoland W Herzog
Roland W Herzog
An international, open-access journal publishing top-quality, novel methods and technology development, as well as significant improvements to established techniques in basic, translational, and clinical cell and gene therapy.

15 June 2017 in Blood
Verified
Journal Article
Open access
PDF file
GRGeoffrey L. Rogers
Geoffrey L. Rogers
JSJamie L. Shirley
Jamie L. Shirley
IZIrene Zolotukhin
Irene Zolotukhin
SKSandeep R. P. Kumar
Sandeep R. P. Kumar
ASAlexandra Sherman
Alexandra Sherman
RHRoland W. Herzog
Roland W. Herzog
Key Points: Crosspriming of AAV capsid-specific CD8+ T cells requires cooperation between distinct subsets of DCs. Innate immune sensing of the viral DNA genome induces cross-presentation of viral capsid in trans.

14 November 2020 in Cellular Immunology
Verified
Journal Article
Closed access
TBThais B. Bertolini
Thais B. Bertolini
MBMoanaro Biswas
Moanaro Biswas
CTCox Terhorst
Cox Terhorst
HDHenry Daniell
Henry Daniell
Roland W HerzogRoland W Herzog
Roland W Herzog
APAnnie R. Pineros
Annie R. Pineros

15 April 2010 in Journal of Virology
Verified
Journal Article
Closed access
ESElankumaran Subbiah
Elankumaran Subbiah
VCVrushali Chavan
Vrushali Chavan
DQDan Qiao
Dan Qiao
RSRaghunath Shobana
Raghunath Shobana
GMGopakumar Moorkanat
Gopakumar Moorkanat
SSSiba K. Samal
Siba K. Samal
Newcastle disease virus (NDV), an avian paramyxovirus, is tumor selective and intrinsically oncolytic because of its potent ability to induce apoptosis. Several studies have demonstrated that NDV is selectively cytotoxic to tumor cells but not normal cells due to defects in the interferon (IFN) antiviral responses of tumor cells. Many naturally occurring strains of NDV have an intact IFN-antagonistic function and can still replicate in normal human cells. To avoid potential toxicity issues with NDV, especially in cancer patients with immunosuppression, safe NDV-oncolytic vectors are needed. We compared the cell killing abilities of (i) a recombinant NDV (rNDV) strain, Beaudette C, containing an IFN-antagonistic, wild-type V protein (rBC), (ii) an isogenic recombinant virus with a mutant V protein (rBC-Edit virus) that induces increased IFN in infected cells and whose replication is restricted in normal human cells, and (iii) a recombinant LaSota virus with a virulent F protein cleavage site that is as interferon sensitive as rBC-Edit virus (LaSota V.F. virus). Our results indicated that the tumor-selective replication of rNDV is determined by the differential regulation of IFN-α and downstream antiviral genes induced by IFN-α, especially through the IRF-7 pathway. In a nude mouse model of human fibrosarcoma, we show that the IFN-sensitive NDV variants are as effective as IFN-resistant rBC virus in clearing the tumor burden. In addition, mice treated with rNDV exhibited no signs of toxicity to the viruses. These findings indicate that augmentation of innate immune responses by NDV results in selective oncolysis and offer a novel and safe virotherapy platform.

7 May 2015 in Blood
Verified
Journal Article
Open access
PDF file
MBMoanaro Biswas
Moanaro Biswas
DSDebalina Sarkar
Debalina Sarkar
SKSandeep R. P. Kumar
Sandeep R. P. Kumar
SNSushrusha Nayak
Sushrusha Nayak
GRGeoffrey L. Rogers
Geoffrey L. Rogers
RHRoland W. Herzog
Roland W. Herzog
Key Points: Rapamycin and Flt3L are synergistic in Treg induction when coadministered with antigen, resulting in improved tolerance induction. pDCs are required for efficient Treg induction and selectively expanded with Flt3L/rapamycin because of high mTOR activity.

1 October 2020 in Cellular Immunology
Verified
Journal Article
Closed access
JRJyoti Rana
Jyoti Rana
MBMoanaro Biswas
Moanaro Biswas